Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
The DOI matches its Crossref record; 373 of the 373 references it cites were found in a registry or an index.
Abstract
Recent times have witnessed an upsurge in the incidence of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Prion disease, and amyotrophic lateral sclerosis. The treatment of the same remains a daunting challenge due to the limited access of therapeutic moieties across the blood–brain barrier. Engineered nanoparticles with a size less than 100 nm provide multifunctional abilities for solving these biomedical and pharmacological issues due to their unique physico‐chemical properties along with capability to cross the blood–brain barrier. Needless to mention, there is a scarcity of review articles summarizing recent developments of various nanomaterials including liposomes, polymeric nanoparticles, metal nanoparticles, and bio‐nanoparticles toward the therapeutic and theranostics applications for various neurodegenerative disorders. Here, a broad spectrum of nanomedicinal approaches to eradicate neurodegenerative disorders is provided, along with a brief account of neuroprotection and neuronal tissue regeneration, current clinical status, issues related to safety, toxicity, challenges, and future outlook.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using nanocarriers like liposomes, nanoparticles, and micelles, radiopharmaceuticals can be protected, ensuring their delicate contents remain intact, while also offering improved compatibility and extended circulation within the body [63].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [63]
In the citing paper
“Owing to their unique physicochemical properties and inherent ability to penetrate the BBB, engineered NPs with dimensions below 100 nm show considerable promise in addressing a range of biological and pharmacological challenges [65].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [65]
Citations
Cites
Items 201–373 of 373
Imaging of Microglia Activation in Stroke
Thiel, A., & Heiss, W.-D. (2011) · Stroke · doi:10.1161/strokeaha.110.598821 · Cited by 124
Yang, L., Yin, T., Liu, Y., Sun, J., Zhou, Y., & Liu, J. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.09.010 · Cited by 124
Development of pharmacological agents for targeting neurotrophins and their receptors
Saragovi, H. U., & Gehring, K. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01444-3 · Cited by 121
Emerging targets and treatments in amyotrophic lateral sclerosis
Zinman, L. H., & Cudkowicz, M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70024-2 · Cited by 121
In vivo study of novel nanofibrous intra-luminal guidance channels to promote nerve regeneration
Koh, H. S., Yong, T., Teo, W. E., Chan, C. K., Puhaindran, M. E., Tan, T. C., Lim, A., Lim, B. H., & Ramakrishna, S. (2010) · Journal of Neural Engineering · doi:10.1088/1741-2560/7/4/046003 · Cited by 119
Accessing neuroinflammation sites: Monocyte/neutrophil-mediated drug delivery for cerebral ischemia
Hou, J., Yang, X., Li, S., Cheng, Z., Wang, Y., Zhao, J., Zhang, C., Li, Y., Luo, M., Ren, H., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau8301 · Cited by 119
Types of neural guides and using nanotechnology for peripheral nerve reconstruction
Biazar, E., Khorasani, M. T., Montazeri, N., Pourshamsian, K., Daliri, M., Rezaei, M., Jabarvand, M., Khoshzaban, A., Heidari, S., Jafarpour, M., et al. (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s11883 · Cited by 118
Molybdenum Disulfide Nanoparticles as Multifunctional Inhibitors against Alzheimer’s Disease
Han, Q., Cai, S., Yang, L., Wang, X., Qi, C., Yang, R., & Wang, C. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b03816 · Cited by 118
Musumeci, T., Serapide, M. F., Pellitteri, R., Dalpiaz, A., Ferraro, L., Magro, R. D., Bonaccorso, A., Carbone, C., Veiga, F., Sancini, G., et al. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.11.002 · Cited by 118
Boado, R. J., Zhou, Q.-H., Lu, J. Z., Hui, E. K.-W., & Pardridge, W. M. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900235k · Cited by 116
The economic cost of Alzheimer's disease: Family or public-health burden?
Castro, D. M., Dillon, C., Machnicki, G., & Allegri, R. (2010) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642010dn40400003 · Cited by 116
Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis
Abdul Razzak, R., Florence, G. J., & Gunn-Moore, F. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123108 · Cited by 112
Zhang, L., Bai, R., Li, B., Ge, C., Du, J., Liu, Y., Guyader, L. L., Zhao, Y., Wu, Y., He, S., et al. (2011) · Toxicology Letters · doi:10.1016/j.toxlet.2011.08.001 · Cited by 109
Regenerative nanomedicine: current perspectives and future directions
Chaudhury, K., Kandasamy, J., S, V. K. H., & RoyChoudhury, S. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s45332 · Cited by 109
Lopes, C. D. F., Gonçalves, N. P., Gomes, C. P., Saraiva, M. J., & Pêgo, A. P. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.12.025 · Cited by 109
Luo, S., Ma, C., Zhu, M.-Q., Ju, W.-N., Yang, Y., & Wang, X. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00021 · Cited by 109
Skaat, H., & Margel, S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.110 · Cited by 107
Nanoscale Dynamics of Amyloid β-42 Oligomers As Revealed by High-Speed Atomic Force Microscopy
Banerjee, S., Sun, Z., Hayden, E. Y., Teplow, D. B., & Lyubchenko, Y. L. (2017) · ACS Nano · doi:10.1021/acsnano.7b05434 · Cited by 107
Lang, A. E. (2010) · Nature Medicine · doi:10.1038/nm.2220 · Cited by 106
Astroglia as a cellular target for neuroprotection and treatment of neuro‐psychiatric disorders
Liu, B., Teschemacher, A. G., & Kasparov, S. (2017) · Glia · doi:10.1002/glia.23136 · Cited by 106
Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis
Dorst, J., Ludolph, A. C., & Huebers, A. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617734734 · Cited by 105
Agyare, E. K., Curran, G. L., Ramakrishnan, M., Yu, C. C., Poduslo, J. F., & Kandimalla, K. K. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9688-y · Cited by 103
Boridy, S., Takahashi, H., Akiyoshi, K., & Maysinger, D. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.06.010 · Cited by 103
Cerium Oxide Nanoparticles: a ‘radical’ Approach to Neurodegenerative Disease Treatment
Naz, S., Beach, J. V., Heckert, B., Tummala, T., Pashchenko, O. I., Banerjee, T., & Santra, S. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0399 · Cited by 103
Siddiqi, K. S., Husen, A., Sohrab, S. S., & Yassin, M. O. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2638-7 · Cited by 101
Nanomedicine for the Treatment of Alzheimer’s Disease
Gregori, M., Masserini, M., & Mancini, S. (2015) · Nanomedicine · doi:10.2217/nnm.14.206 · Cited by 99
Liu, W., Wong, A., Au, L., Yang, J., Wang, Z., Leung, E. Y. L., Chen, S., Ho, C. L., & Mok, V. C. T. (2015) · Stroke · doi:10.1161/strokeaha.115.010449 · Cited by 99
Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective
Soni, S., Ruhela, R. K., & Medhi, B. (2016) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2016.044 · Cited by 99
Chelation therapy for neurodegenerative diseases
Bolognin, S., Drago, D., Messori, L., & Zatta, P. (2009) · Medicinal Research Reviews · doi:10.1002/med.20148 · Cited by 97
Songjiang, Z., & Wu, L. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-009-9279-1 · Cited by 96
Malmo, J., Sandvig, A., Vårum, K. M., & Strand, S. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054182 · Cited by 95
Personalized nanomedicine for CNS diseases
Kaushik, A., Jayant, R. D., Bhardwaj, V., & Nair, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2017.11.010 · Cited by 95
Bourassa, P., Alata, W., Tremblay, C., Paris-Robidas, S., & Calon, F. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00870 · Cited by 95
Mendiratta, S., hussein, M., Nasser, H. A., & Ali, A. (2019) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.201900195 · Cited by 95
Pai, A., Rubinstein, I., & Önyüksel, H. (2006) · Peptides · doi:10.1016/j.peptides.2006.04.022 · Cited by 91
During, M. J., Freese, A., Deutch, A. Y., Kibat, P. G., Sabel, B. A., Langer, R., & Roth, R. H. (1992) · Experimental Neurology · doi:10.1016/0014-4886(92)90053-s · Cited by 90
Crawford, L., Rosch, J. G., & Putnam, D. A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.041 · Cited by 90
α-Synuclein-carrying extracellular vesicles in Parkinson’s disease: deadly transmitters
Chistiakov, D. A., & Chistiakov, A. A. (2016) · Acta Neurologica Belgica · doi:10.1007/s13760-016-0679-1 · Cited by 90
Edaravone: a new treatment for ALS on the horizon?
Hardiman, O. M., & van den Berg, L. H. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30163-1 · Cited by 90
Chen, T., Li, C., Li, Y., Yi, X., Wang, R., Lee, S. M.-Y., & Zheng, Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b01171 · Cited by 89
Neuroprotective and Antioxidant Effect of Naringenin-Loaded Nanoparticles for Nose-to-Brain Delivery
Md, S., Alhakamy, N. A., Aldawsari, H. M., & Asfour, H. Z. (2019) · Brain Sciences · doi:10.3390/brainsci9100275 · Cited by 89
Protective properties of melatonin-loaded nanoparticles against lipid peroxidation
Schaffazick, S. R., Pohlmann, A. R., de Cordova, C. A. S., Creczynski‐Pasa, T. B., & Guterres, S. S. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.11.003 · Cited by 88
Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems
Garbayo, E., Ansorena, E., & Blanco‐Prieto, M. J. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.05.019 · Cited by 88
The use of accelerometry as a tool to measure disturbed nocturnal sleep in Parkinson’s disease
McGregor, S., Churchward, P., Soja, K., O’Driscoll, D. M., Braybrook, M., Khodakarami, H., Evans, A. H., Farzanehfar, P., Hamilton, G. S., & Horne, M. K. (2018) · npj Parkinson s Disease · doi:10.1038/s41531-017-0038-9 · Cited by 88
Micro- and nanotechnology approaches to improve Parkinson's disease therapy
Torres-Ortega, P. V., Saludas, L., Hanafy, A. S., Garbayo, E., & Blanco‐Prieto, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.036 · Cited by 88
Is Neurotoxicity of Metallic Nanoparticles the Cascades of Oxidative Stress?
Song, B., Zhang, Y., Liu, J., Feng, X., Zhou, T., & Shao, L. (2016) · Nanoscale Research Letters · doi:10.1186/s11671-016-1508-4 · Cited by 87
Molecular Interactions of Dendrimers with Amyloid Peptides: pH Dependence
Klajnert‐Maculewicz, B., Cladera, J., & Bryszewska, M. J. (2006) · Biomacromolecules · doi:10.1021/bm060229s · Cited by 86
Patel, D. A., Henry, J. E., & Good, T. A. (2007) · Brain Research · doi:10.1016/j.brainres.2007.05.055 · Cited by 86
Gold Nanoparticles and Microwave Irradiation Inhibit Beta-Amyloid Amyloidogenesis
Araya, E., Olmedo, I., Bastús, N. G., Guerrero, S., Puntes, V., Giralt, E., & Kogan, M. J. (2008) · Nanoscale Research Letters · doi:10.1007/s11671-008-9178-5 · Cited by 86
60 YEARS OF POMC: From POMC and α-MSH to PAM, molecular oxygen, copper, and vitamin C
Kumar, D., Mains, R. E., & Eipper, B. A. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0266 · Cited by 86
Venkataramani, V., Doeppner, T. R., Willkommen, D., Cahill, C. M., Xin, Y., Ye, G., Liu, Y., Southon, A. G., Aron, A. T., Au‐Yeung, H. Y., et al. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14580 · Cited by 86
Use of Polyamidoamine Dendrimers in Brain Diseases
Florendo, M., Figacz, A., Srinageshwar, B., Sharma, A., Swanson, D., Dunbar, G. L., & Rossignol, J. (2018) · Molecules · doi:10.3390/molecules23092238 · Cited by 86
Bihel, E., Pró-Sistiaga, P., Letourneur, A., Toutain, J., Saulnier, R., Insausti, R., Bernaudin, M., Roussel, S., & Touzani, O. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.209 · Cited by 85
Karaboğa, M. N. S., & Sezgintürk, M. K. (2018) · The Analyst · doi:10.1039/c8an01279b · Cited by 83
Williams, S. R., Lepene, B. S., Thatcher, C. D., & Long, T. E. (2008) · Biomacromolecules · doi:10.1021/bm801058j · Cited by 82
Amphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders
Rakotoarisoa, M., & Angelova, A. (2018) · Medicines · doi:10.3390/medicines5040126 · Cited by 82
Yuan, M., Wang, Y., & Qin, Y. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.03.004 · Cited by 81
Nanomedicine for treating spinal cord injury
Tyler, J. Y., Xu, X.-M., & Cheng, J.-X. (2013) · Nanoscale · doi:10.1039/c3nr00957b · Cited by 80
Intracellular Signal Modulation by Nanomaterials
Hussain, S., Garantziotis, S., Rodrigues‐Lima, F., Dupret, J., Baeza‐Squiban, A., & Boland, S. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-8739-0_7 · Cited by 79
Drug Delivery Systems for Imaging and Therapy of Parkinson';s Disease
Silindir Gunay, M., Yekta Ozer, A., & Chalon, S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151230124904 · Cited by 79
Gelatin/nanoceria nanocomposite fibers as antioxidant scaffolds for neuronal regeneration
Marino, A., Tonda‐Turo, C., Pasquale, D. D., Ruini, F., Genchi, G. G., Nitti, S., Cappello, V., Gemmi, M., Mattoli, V., Ciardelli, G., et al. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.11.022 · Cited by 79
Kang, M. K., Lee, J., Nguyen, A. H., & Sim, S. J. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.05.017 · Cited by 78
Son, M. ‐., Sim, H., Son, Y. S., Jung, K. B., Lee, M. ‐., Oh, J. ‐., Chung, S. ‐., Jung, C. ‐., & Kim, J. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12396 · Cited by 78
Zhang, Y., & Pardridge, W. M. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9815-9 · Cited by 77
CNS organoids: an innovative tool for neurological disease modeling and drug neurotoxicity screening
Chhibber, T., Bagchi, S., Lahooti, B., Verma, A., Al-Ahmad, A., Paul, M. K., Pendyala, G., & Jayant, R. D. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.010 · Cited by 77
Self-citationLongitudinal thalamic diffusion changes after middle cerebral artery infarcts
Herve, D. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.041012 · Cited by 76
Prions and protein-folding diseases: Review: Prions and protein-folding diseases
Norrby, E. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02387.x · Cited by 75
α-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities
Lööv, C., Scherzer, C. R., Hyman, B. T., Breakefield, X. O., & Ingelsson, M. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0317-0 · Cited by 75
Wu, Y.-Y., Chiu, F.-L., Yeh, C.-S., & Kuo, H.-C. (2019) · Open Biology · doi:10.1098/rsob.180177 · Cited by 75
Seizure remission in adults with long-standing intractable epilepsy: An extended follow-up
Choi, H., Heiman, G. A., Clary, H. M. M., et al. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.11.005 · Cited by 74
Methods for Analysis of Amyloid-β Aggregates
Bruggink, K. A., Müller, M., Kuiperij, H. B., & Verbeek, M. M. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-111421 · Cited by 73
Antibody‐Mimetic Peptoid Nanosheet for Label‐Free Serum‐Based Diagnosis of Alzheimer's Disease
Zhu, L., Zhao, Z., Cheng, P., He, Z., Cheng, Z., Peng, J., Wang, H., Wang, C., Yang, Y., & Hu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201700057 · Cited by 71
da Cruz, M. T. G., Cardoso, A. L., de Almeida, L. P., Simões, S., & de Lima, M. C. P. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302516 · Cited by 70
Agustín‐Pavón, C., Mielcarek, M., Garriga-Canut, M., & Isalan, M. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0128-x · Cited by 70
Available and emerging treatments for Parkinson’s disease: a review
Stacy, M. A., Hickey, P., & Stacy, M. A. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s11836 · Cited by 68
Ghavami, M., Rezaei, M., Ejtehadi, M. R., Lotfi, M., Shokrgozar, M. A., Emami, B. A., Raush, J., & Mahmoudi, M. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300205g · Cited by 68
Improved bioavailability of orally administered mifepristone from PLGA nanoparticles
HE, W., HORN, S., & HUSSAIN, M. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.10.025 · Cited by 67
Non-invasive approaches for drug delivery to the brain based on the receptor mediated transport
Fang, F., Zou, D., Wang, W., Yin, Y., Yin, T., Hao, S., Wang, B., Wang, G., & Wang, Y. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.02.056 · Cited by 65
Sumbria, R. K., Hui, E. K.-W., Lu, J. Z., Boado, R. J., & Pardridge, W. M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400348n · Cited by 64
Schaffazick, S. R., Siqueira, I. R., Badejo, A. S., Jornada, D. S., Pohlmann, A. R., Netto, C. A., & Guterres, S. S. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.11.010 · Cited by 64
Fernandes, C., Martins, C., Fonseca, A., Nunes, R., Matos, M. J., Silva, R., Garrido, J., Sarmento, B., Remião, F., Otero-Espinar, F. J., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b17224 · Cited by 63
Nanotechnology for CNS delivery of bio-therapeutic agents
Shah, L., Yadav, S., & Amiji, M. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0133-3 · Cited by 61
Gold Nanoparticles as a Probe for Amyloid-β Oligomer and Amyloid Formation
Elbassal, E. A., Morris, C., Kent, T. W., Lantz, R., Ojha, B., Wojcikiewicz, E. P., & Du, D. (2017) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.7b05169 · Cited by 61
Optimization of fully aligned bioactive electrospun fibers for “in vitro” nerve guidance
Cirillo, V., Guarino, V., Álvarez-Pérez, M. A., Marrese, M., & Ambrosio, L. (2014) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-014-5214-4 · Cited by 60
Rapid α-oligomer formation mediated by the Aβ C terminus initiates an amyloid assembly pathway
Misra, P., Kodali, R., Chemuru, S., Kar, K., & Wetzel, R. (2016) · Nature Communications · doi:10.1038/ncomms12419 · Cited by 60
Ferraro, S. A., Domingo, M. G., Etcheverrito, A., Olmedo, D. G., & Tasat, D. R. (2020) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2019.126413 · Cited by 60
Siegemund, T., Paulke, B. ‐., Schmiedel, H., Bordag, N., Hoffmann, A., Harkany, T., Tanila, H., Kacza, J., & Härtig, W. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.012 · Cited by 59
A drug delivery hydrogel system based on activin B for Parkinson's disease
Li, J., Darabi, M.-A., Gu, J., Shi, J., Xue, J., Huang, L. H., Liu, Y., Zhang, L., Liu, N., Zhong, W., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.016 · Cited by 58
Thompson, L. M. (2008) · Nature · doi:10.1038/452707a · Cited by 57
Carrier-mediated transport to enhance drug delivery to brain
Smith, Q. R. (2005) · International Congress Series · doi:10.1016/j.ics.2005.02.012 · Cited by 57
Giordano, C., Albani, D., Gloria, A., Tunesi, M., Batelli, S., Russo, T., Forloni, G., Ambrosio, L., & Cigada, A. (2009) · The International Journal of Artificial Organs · doi:10.1177/039139880903201202 · Cited by 57
Mazibuko, Z., Choonara, Y. E., Kumar, P., du Toit, L. C., Modi, G., Naidoo, D., & Pillay, V. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24322 · Cited by 56
Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson’s Disease
van Wamelen, D. J., Grigoriou, S., Chaudhuri, К. R., & Odin, P. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181476 · Cited by 56
Laquinimod in the treatment of multiple sclerosis: a review of the data so far
Thöne, J., & Linker, R. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s55308 · Cited by 54
Surnar, B., Basu, U., Banik, B., Ahmad, A., Marples, B., Kolishetti, N., & Dhar, S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816429115 · Cited by 54
In deep evaluation of the neurotoxicity of orally administered TiO2 nanoparticles
Grissa, I., Ghoul, J. M. E., Mrimi, R., Mir, L. E., Cheikh, H. B., & Horcajada, P. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.10.005 · Cited by 54
Controlled delivery of dopamine hydrochloride using surface modified carbon dots for neuro diseases
Khan, M. S., Pandey, S., Talib, A., Bhaisare, M. L., & Wu, H. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.06.006 · Cited by 53
Stefano, A. D., Carafa, M., Sozio, P., Pinnen, F., Braghiroli, D., Orlando, G., Cannazza, G., Ricciutelli, M., Marianecci, C., & Santucci, E. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.010 · Cited by 53
Choi, J.-S., Choi, H. J., Jung, D. C., Lee, J.-H., & Cheon, J. (2008) · Chemical Communications · doi:10.1039/b803294g · Cited by 53
Ong, L. K., Zhao, Z., Kluge, M. G., Walker, F. R., & Nilsson, M. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16654920 · Cited by 53
Xue, J., Liu, Y., Darabi, M. A., Tu, G., Huang, L., Ying, L., Xiao, B., Wu, Y., Xing, M., Zhang, L., et al. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.03.024 · Cited by 53
Du, Q., Ge, D., Mirshafiee, V., Chen, C., Li, M., Xue, C., Ma, X., & Sun, B. (2019) · Nanoscale · doi:10.1039/c9nr03756j · Cited by 52
Receptor-Mediated Abeta Amyloid Antibody Targeting to Alzheimer’s Disease Mouse Brain
Zhou, Q.-H., Fu, A., Boado, R. J., Hui, E. K.-W., Lu, J. Z., & Pardridge, W. M. (2011) · Molecular Pharmaceutics · doi:10.1021/mp1003515 · Cited by 51
Application of Nanodiagnostics and Nanotherapy to CNS Diseases
Zhang, W., Wang, W., Yu, D. X., Xiao, Z., & He, Z. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0163 · Cited by 50
Sahathevan, R., Linden, T. K. A., Villemagne, V. L., Churilov, L. P., Ly, J. V., Rowe, C. C., Donnan, G. A., & Brodtmann, A. G. (2015) · Stroke · doi:10.1161/strokeaha.115.010528 · Cited by 49
Clinical Trials for Neuroprotection in ALS
Siciliano, G., Carlesi, C., Pasquali, L., Piazza, S., Pietracupa, S., Fornai, F., Ruggieri, S., & Murri, L. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791292648 · Cited by 48
Veronesi, M. C., Aldouby, Y., Domb, A. J., & Kubek, M. J. (2009) · Brain Research · doi:10.1016/j.brainres.2009.09.039 · Cited by 47
Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation
Kubek, M. J., Liang, D., Byrd, K. E., & Domb, A. J. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00860-9 · Cited by 47
Correia, A. T., Rebelo, D., Marques, J., & Nunes, B. (2019) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2019.02.012 · Cited by 47
Technology Insight: imaging neurodegeneration in Parkinson's disease
Brooks, D. J. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0773 · Cited by 46
Brain drug delivery by adsorption-mediated transcytosis
Zhu, X., Jin, K., Huang, Y., & Pang, Z. (2019) · Brain Targeted Drug Delivery System · doi:10.1016/b978-0-12-814001-7.00007-x · Cited by 46
LeWitt, P. A., Giladi, N., & Navon, N. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.05.032 · Cited by 46
Yang, J. A., Lin, W., Woods, W. S., George, J. M., & Murphy, C. J. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp501114h · Cited by 45
Ji, B., Wang, M., Gao, D., Xing, S., Li, L., Liu, L., Zhao, M., Qi, X., & Dai, K. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0267 · Cited by 45
Conti, E., Gregori, M., Radice, I., Da Re, F., Grana, D., Re, F., Salvati, E., Masserini, M., Ferrarese, C., Zoia, C. P., et al. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.02.012 · Cited by 45
Alemdar, A. Y., Sadi, D., McAlister, V. C., et al. (2004) · Cell Transplantation · doi:10.3727/000000004783983936 · Cited by 44
Saraiva, A. M., Cardoso, I., Saraiva, M. J., Tauer, K., Pereira, M. D. C., Coelho, M. A. N., Möhwald, H., & Brezesinski, G. (2010) · Macromolecular Bioscience · doi:10.1002/mabi.200900448 · Cited by 43
Strategies for clinical approach to neurodegeneration in Amyotrophic lateral sclerosis.
Carlesi, C., Pasquali, L., Piazza, S., Gerfo, A. L., Ienco, E. C., Alessi, R., Fornai, F., & Siciliano, G. (2011) · PubMed · doi:10.4449/aib.v149i1.1267 · Cited by 42
Zeevalk, G. D., Bernard, L. P., & Guilford, F. T. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0217-0 · Cited by 42
Fontes, M. A. P., Vaz, G. C., Cardoso, T. Z. D., Oliveira, M. F., Campagnole‐Santos, M. J., Santos, R. A. S., Sharma, N. M., Patel, K. P., & Frézard, F. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.12.007 · Cited by 42
Marotta, N., Kim, S., & Krainc, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1703671 · Cited by 42
Kamalinia, G., Khodagholi, F., Shaerzadeh, F., Tavssolian, F., Chaharband, F., Atyabi, F., Sharifzadeh, M., Amini, M., & Dinarvand, R. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12586 · Cited by 41
Metal Nanoparticles for the Treatment and Diagnosis of Neurodegenerative Brain Diseases
Vío, V., Marchant, M. J., Araya, E., & Kogan, M. J. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170105152948 · Cited by 41
Animal Models of Polyglutamine Diseases and Therapeutic Approaches
Marsh, J., Lukácsovich, T., & Thompson, L. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800065200 · Cited by 40
β-Amyloid Aggregation in Human Brains With Cerebrovascular Lesions
Aho, L., Jolkkonen, J., & Alafuzoff, I. (2006) · Stroke · doi:10.1161/01.str.0000248777.44128.93 · Cited by 40
Neurodegenerative Diseases: Challenges And Opportunities
Cuny, G. D. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.123 · Cited by 39
Pavičić, I., Milić, M., Pongrac, I. M., Ahmed, L. B., Glavan, T. M., Ilić, K., Zapletal, E., Ćurlin, M., Mitrečić, D., & Vrček, I. V. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110935 · Cited by 39
Ahmed, B., Yusuf, M., Khan, M., & Khan, R. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s34588 · Cited by 38
Patience, M., Zouikr, I., Jones, K., Clarkson, A. N., Isgaard, J., Johnson, S. J., Walker, F. R., & Nilsson, M. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1487-8 · Cited by 38
Bataveljić, D., Stamenković, S., Bačić, G., & Andjus, P. (2011) · Acta Physiologica Hungarica · doi:10.1556/aphysiol.98.2011.1.4 · Cited by 38
Lin, D., He, R., Li, S., Xu, Y., Wang, J., Wei, G., Ji, M., & Yang, X. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00244 · Cited by 38
Li, C., Ling, X., Liu, S., Xu, A., Zhang, Y., Xing, S., Pei, Z., & Zeng, J. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-49 · Cited by 37
Nanomedicine Approaches to Modulate Neural Stem Cells in Brain Repair
Santos, T., Boto, C., Saraiva, C., Bernardino, L. I., & Ferreira, L. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2016.02.003 · Cited by 37
Ai Tran, H. N., Sousa, F., Moda, F., Mandal, S., Chanana, M., Vimercati, C., Morbin, M., Krol, S., Tagliavini, F., & Legname, G. (2010) · Nanoscale · doi:10.1039/c0nr00551g · Cited by 35
Kunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Self-citationPharmacoresistant epilepsy and nanotechnology
la Torre, A. R.-D., Luna-Bárcenas, G., Orozco-Suárez, S., Salgado-Ceballos, H., García, P., Lazarowski, A., & Rocha, L. (2014) · Frontiers in Bioscience-Elite · doi:10.2741/709 · Cited by 34
Neurotoxicity assessment of oleic acid-coated iron oxide nanoparticles in SH-SY5Y cells
Fernández‐Bertólez, N., Costa, C., Brandão, F., Kılıç, G., Teixeira, J. P., Pásaro, E., Laffón, B., & Valdiglesias, V. (2018) · Toxicology · doi:10.1016/j.tox.2018.06.003 · Cited by 33
Albani, D., Gloria, A., Giordano, C., et al. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/270260 · Cited by 32
Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia
Müller, T. H., Kuhn, W., & Möhr, J.-D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1612365 · Cited by 32
Nanoparticles and neurotoxicity: Dual response of glutamatergic receptors
Engin, A. B., & Engin, A. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.005 · Cited by 31
Wang, Y., Wang, Y., Sun, R., Wu, X., Chu, X., Zhou, S., Hu, X., Gao, L., & Kong, Q. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1712-3 · Cited by 31
Brain Drug Delivery System Bearing Dopamine Hydrochloride for Effective Management of Parkinsonism
Jain, N., Rana, A. C., & Jain, S. (1998) · Drug Development and Industrial Pharmacy · doi:10.3109/03639049809082370 · Cited by 29
Depressive disorders in patients with pharmaco-resistant mesial temporal lobe epilepsy
Gonçalves, E. B., Cardoso, T. A. M. D. O., Yasuda, C. L., & Cendes, F. (2017) · Journal of International Medical Research · doi:10.1177/0300060517717825 · Cited by 29
Long, Q., Li, J., Luo, Q., Hei, Y., Wang, K., Tian, Y., Yang, J., Lei, H., Qiu, B., & Liu, W. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.08.040 · Cited by 28
Härtig, W., Kacza, J., Paulke, B., Grosche, J., Bauer, U. U. I., Hoffmann, A., Elsinghorst, P. W., & Gütschow, M. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.07038.x · Cited by 28
Imaging the urinary pathways in mice by liposomal indocyanine green
Portnoy, E., Nizri, E., Golenser, J., Shmuel, M., Magdassi, S., & Eyal, S. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.02.019 · Cited by 28
Nanomedicine for prion disease treatment
McCarthy, J. M., Appelhans, D., Tatzelt, J., et al. (2013) · Prion · doi:10.4161/pri.24431 · Cited by 26
Critical role of transglutaminase and other stress proteins during neurodegenerative processes
Caccamo, D., Currò, M., Condello, S., Ferlazzo, N., & Ientile, R. (2009) · Amino Acids · doi:10.1007/s00726-009-0428-3 · Cited by 26
Chowdhury, S. R., Agarwal, M., Meher, N., Balakrishnan, M., & Iyer, P. K. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b03668 · Cited by 26
Dendrimers antiamyloidogenic potential in neurodegenerative diseases
Benseny‐Cases, N., Klementieva, O. L., & Cladera, J. (2011) · New Journal of Chemistry · doi:10.1039/c1nj20469f · Cited by 25
Neurotoxic and Neuroprotective Role of Exosomes in Parkinson’s Disease
Longoni, B., Fasciani, I., Kolachalam, S., Pietrantoni, I., Marampon, F., Petragnano, F., Aloisi, G., Coppolino, M. F., Rossi, M., Scarselli, M., et al. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191113103537 · Cited by 25
Monocytes as Carriers of Magnetic Nanoparticles for Tracking Inflammation in the Epileptic Rat Brain
Han, H., Eyal, S., Portnoy, E., Mann, A., Shmuel, M., Benifla, M., Ekstein, D., & Polyak, B. (2019) · Current Drug Delivery · doi:10.2174/1567201816666190619122456 · Cited by 23
Gondim, B. L. C., Catarino, J. D. S., de Sousa, M. A. D., Silva, M. D. O., Lemes, M. R., Carvalho-Costa, T. M., Nascimento, T. R. D. L., Machado, J. R., Rodrigues, V., Oliveira, C. J. F., et al. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191014171354 · Cited by 23
Xie, M., Kan, L., Huang, B.-H., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.07.063 · Cited by 22
Elkurd, M. T., Bahroo, L. B., & Pahwa, R. (2018) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0001 · Cited by 22
Ellermann, C., Coenen, A., Niehues, P., Leitz, P. R., Kochhäuser, S., Dechering, D. G., Fehr, M., Eckardt, L., & Frommeyer, G. (2019) · Cardiovascular Toxicology · doi:10.1007/s12012-019-09543-8 · Cited by 22
Cederfjäll, E. A., Broom, L., & Kirik, D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.8 · Cited by 21
Paik, J., & Keam, S. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0552-2 · Cited by 20
Mondal, S., Chowdhury, S. R., Shah, M., Kumar, V., Kumar, S., & Iyer, P. K. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00128 · Cited by 18
Building a Human Brain for Research
Bitar, M., & Barry, G. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00022 · Cited by 18
Development of drug-loaded polymer microcapsules for treatment of epilepsy
Chen, Y., Gu, Q., Yue, Z., Crook, J. M., Moulton, S. E., Cook, M. J., & Wallace, G. G. (2017) · Biomaterials Science · doi:10.1039/c7bm00623c · Cited by 17
Pinto, M., Fernandes, C., Gil-Martins, E., Silva, R. V. D. S., Benfeito, S., Cagide, F., Mendes, R. F., Paz, F. A. A., Garrido, J., Remião, F., et al. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070331 · Cited by 17
Nanotechnology As Potential Tool for siRNA Delivery in Parkinson's Disease
Cortés, H., Alcalá-Alcalá, S., Ávalos‐Fuentes, A., et al. (2017) · Current Drug Targets · doi:10.2174/1389450118666170321130003 · Cited by 16
Lack of secondary pathology in the thalamus after focal cerebral ischemia in nonhuman primates
Lipsanen, A., Kalesnykas, G., Pró-Sistiaga, P., Hiltunen, M. O., Vanninen, R. L., Bernaudin, M., Touzani, O., & Jolkkonen, J. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.06.016 · Cited by 14
Yurasov, V. V., Kucheryanu, V. G., Кудрин, В. С., Zhigaltsev, I. V., Никушкин, Е. В., Sandalov, Y. G., Kaplun, A. P., & Швец, В. И. (1997) · Bulletin of Experimental Biology and Medicine · doi:10.1007/bf02766431 · Cited by 12
The year in review: progress in brain barriers and brain fluid research in 2018
Keep, R. F., Jones, H. C., & Drewes, L. R. (2019) · Fluids and Barriers of the CNS · doi:10.1186/s12987-019-0124-y · Cited by 12
Mondal, S., Kumar, V., Chowdhury, S. R., Shah, M., Gaur, A., Kumar, S., & Iyer, P. K. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00514 · Cited by 10
Jia, J., Ji, Y., Feng, T., Ye, Q., Peng, D., Kuang, W., Ning, Y., Liang, Z., Fan, D., Wei, W., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190791 · Cited by 10
Claassen, D. O., Iyer, R. G., Shah‐Manek, B., DiBonaventura, M., Abler, V., & Sung, V. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170286 · Cited by 8
Dendrimers in Neurodegenerative Diseases
Šebestı́k, J., Reiniš, M., & Ježek, J. (2012) · Springer eBooks · doi:10.1007/978-3-7091-1206-9_23 · Cited by 5
Assessment of the Nature Interactions of β-Amyloid Protein by a Nanoprobe Method
Caballero, L., Mena, J. F., Morales-Alvarez, A., Kogan, M. J., & Melo, F. (2014) · Langmuir · doi:10.1021/la502777h · Cited by 5
la Torre, A., Rocha, L., Salgado‐Ceballos, H., et al. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557516666161013105000 · Cited by 4
Lewin, N., Aksay, E. R. F., & Clancy, C. E. (2013) · PLoS ONE · doi:10.1371/annotation/d6af29ee-25c0-4f8e-910e-afe53ef8f963 · Cited by 1
Research works printed but not linked: 13
- Birks J. S., 2018, Cochrane Database Syst. Rev., 6, CD001190
- Carlesi C., 2011, Arch. Ital. Biol., 149, 151
- Chen W., 2018, Adv. Mater., 30
- Fu T., 2016, Neural Plast., 2016, 1
- Wang Y. L., 2018, Zhonghua Yixue Zazhi, 98, 2678
- Cummings J., 2017, J. Prev. Alzheimers Dis., 4, 109
- Hickey P., 2011, Drug Des., Dev. Ther., 5, 241
- Fernandez H. H., 2016, npj Parkinson's Dis., 2, 1
- 10.1002/adma.201801362 · DOI · Paper page
- Shin J. W., 2016, Hum. Mol. Genet., 25, 4566
- Sone D., 2019, Mol. Psychiatry
- Yusuf M., 2012, Int. J. Nanomed., 7, 4311
- Carpenter D. O., 2001, Int. J. Occup. Med. Environ. Health, 14, 209
Cited by
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Self-citationOuyang, J., Xie, A., Zhou, J., Liu, R., Wang, L., Liu, H., Kong, N., & Tao, W. (2022) · Chemical Society Reviews · doi:10.1039/d1cs01148k · Cited by 385
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144
“Using nano-carriers like liposomes, nanoparticles, and micelles, radiopharmaceuticals can be protected, ensuring their delicate contents remain intact, while also offering improved compatibility and extended circulation within the body [63].”
BackgroundLa Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Moorthy, H., & Govindaraju, T. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01319 · Cited by 64
Metadata
- Authors
- Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A.
- Affiliations
- Rice University (US)
- Mayo Clinic (US)
- Birla Institute of Technology and Science, Pilani (IN)
- Department of Pharmaceutical Sciences College of Pharmacy University of Nebraska Medical Center 986025 Nebraska Medical Center Omaha NE 68198‐6025 USA
- University of California, Los Angeles (US)
- Aavishkar Oral Strips Pvt. Ltd. 109/3, IDA, Phase 2, Sector 2, Lane 6, Cherlapally Hyderabad Telangana 500051 India
- Corresponding author
- Mukherjee, Sudip
- Paul, Manash Kumar
- Mukherjee, Anubhab
- Venue
- Advanced Functional Materials
- Publisher
- Wiley
- Published
- 2020-06-16
- Volume
- 30
- Issue
- 35
- ISSN
- 1616-301X (ISSN-L)
- 1616-3028
- OpenAlex
- W3036302963
- Cited by
- 152
- References
- 373
- Citations by year
- 2026: 12 · 2025: 32 · 2024: 29 · 2023: 24 · 2022: 29 · 2021: 22 · 2020: 4
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Functional Materials (publishedVersion)
- Funders
- Rice University
- University of California, Los Angeles
- Mayo Clinic
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- nanomedicine, neurodegenerative diseases, theranostics, blood-brain barrier, engineered nanoparticles, liposomes, polymeric nanoparticles, metal nanoparticles, bionanoparticles, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, amyotrophic lateral sclerosis, neuroprotection, nanoparticle toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.